Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform
Oncology Pharma Inc. (OTC PINK:ONPH) announced a White Paper highlighting five innovative strategies to enhance patient engagement in clinical trials, focusing on Health Literacy, Patient Concierge Services, Trial Support Communities, User-Friendly Interfaces, and Data Empowerment. The White Paper is available on their website. The company aims to further develop its Connect2Med platform to improve clinical trial experiences and increase engagement globally. The platform integrates seamlessly with existing systems, providing valuable insights for sponsors and enhancing patient retention.
- Introduction of a White Paper outlining 5 strategies to enhance patient engagement.
- Focus on developing the Connect2Med platform for better clinical trial experiences.
- Seamless integration of Connect2Med with major industry systems, enhancing workflow.
- Access to impactful data and metrics for strategic decision-making.
- Current negative operating cash flows indicate potential financial instability.
- Need for additional funding could be highly dilutive to existing shareholders.
- Uncertain market acceptance for new technologies may hinder growth.
- Risks associated with licensing arrangements and potential legal issues.
SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') is releasing a White Paper outlining 5 innovative ways to improve patient engagement in clinical trials. The five key points in the White Paper (which can be found here: https://www.oncology-pharma.com/white-papers are: Health Literacy, Patient Concierge Service, Trial Support Community, Easy-to-use User Interface, and Empowering with data. Oncology Pharma is delighted to advance this technology and looks forward to utilizing the platform for its studies involving our licensed IP utilizing its features and increasing engagement and efficiencies. Further, Oncology Pharma will seek to advance the platform to be utilized and made available for studies and clinical trials on a worldwide basis.
Connect2Med is a patient engagement and retention platform designed to improve the clinical trial experience for both patients and providers. With Connect2Med, sponsors, CROs, and sites have a place for leads, or people in their databases, to 'live' in an online community. The platform provides a private, secure space where people interested in or recruited to clinical trials have a safe, closed community they can join that provides trustworthy information and compassionate connections to support them on their journey.
Connect2Med provides a motivating trial experience through increased engagement and easy to use communication tools. They have access to a dedicated trial specific portal (patient facing app), where they can perform functions like eDiary, ePRO and telehealth visits. The platform is FHIR compatible and easily integrates with EHR, CTMS, CRM from major vendors in the industry. Patients' workflow can be automated through a set of digital workflows, with automated interventions and escalation when needed. Sites and CROs can post upcoming trials in a public space for all to see, boosting public awareness through social sharing. Site owners and Sponsors have access to impactful data, metrics and reports that allow them to make strategic decisions to improve retention, growth, performance, satisfaction and ROI.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
ABOUT Ribera Solutions, LLC (www.riberasolutions.com)
Ribera Solutions (CA, USA) has developed Web based Connect2Med platform with iOS and Android mobile Apps. Ribera's mission is to provide solutions for solving challenging problems timely through simple, practical and economical approaches.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACT:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/651012/Oncology-Pharma-and-Ribera-Solutions-Release-White-Paper-Regarding-Patient-Engagement-and-Retention-Platform
FAQ
What are the key strategies highlighted in Oncology Pharma's White Paper?
How does the Connect2Med platform improve clinical trials?
What risks does Oncology Pharma face according to their press release?
When was the White Paper by Oncology Pharma released?
What stock symbol represents Oncology Pharma?
